Neutrophil‑to‑lymphocyte ratio and risk of disease progression in patients with nivolumab‑treated unresectable or recurrent gastric cancer

Hayashi,Hirokatsu; Yasufuku,Itaru; Sato,Yuta; Fujibayashi,Seito; Chikaishi,Wakana; Endo,Masahide; Horaguchi,Takeshi; Yokoi,Ryoma; Matsumoto,Keita; Kuno,Masashi; Sengoku,Yuki; Fukada,Masahiro; Asai,Ryuichi; Tajima,Jesse Yu; Makiyama,Akitaka; Kiyama,Shigeru; Tanaka,Yoshihiro; Murase,Katsutoshi; Ishihara,Takuma; Matsuhashi,Nobuhisa

doi:10.3892/ol.2024.14766

Neutrophil‑to‑lymphocyte ratio and risk of disease progression in patients with nivolumab‑treated unresectable or recurrent gastric cancer

Authors:
- Hirokatsu Hayashi
- Itaru Yasufuku
- Yuta Sato
- Seito Fujibayashi
- Wakana Chikaishi
- Masahide Endo
- Takeshi Horaguchi
- Ryoma Yokoi
- Keita Matsumoto
- Masashi Kuno
- Yuki Sengoku
- Masahiro Fukada
- Ryuichi Asai
- Jesse Yu Tajima
- Akitaka Makiyama
- Shigeru Kiyama
- Yoshihiro Tanaka
- Katsutoshi Murase
- Takuma Ishihara
- Nobuhisa Matsuhashi
View Affiliations

Affiliations: Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Gifu 501‑1194, Japan, Cancer Center, Gifu University Hospital, Gifu, Gifu 501‑1194, Japan, Innovative and Clinical Research Promotion Center, Gifu University Hospital, Gifu, Gifu 501‑1194, Japan
Published online on: October 22, 2024 https://doi.org/10.3892/ol.2024.14766
Article Number: 20
Copyright: © Hayashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Studies have associated neutrophil‑to‑lymphocyte ratio (NLR) with overall survival (OS) and progression‑free survival (PFS) in patients with gastric cancer (GC). The present study aimed to examine the relationship between dynamic changes in NLR during treatment and disease progression in patients with unresectable or recurrent GC treated with nivolumab monotherapy as a third‑line or later regimen. Patients treated with nivolumab as a third‑line or later therapy for unresectable or recurrent GC at Gifu University Hospital (Gifu, Japan) from April 2017 to December 2021 were included. Pretreatment data and those obtained every 2 weeks after the treatment commenced were evaluated. The association between all NLR values and disease progression for each patient was evaluated using a time‑dependent Cox proportional hazards model and restricted cubic spline (RCS) curves. The study included 44 patients (23 men and 21 women). The response and disease control rates were 6.8 and 27.3%, respectively. The median PFS and OS of all patients were 1.84 months [95% confidence interval (CI), 1.32‑2.14] and 5.93 months (95% CI, 3.75‑10.75), respectively. The risk for progressive disease (PD) increased with higher NLR (hazard ratio, 2.25; 95% CI, 1.3‑3.87). The RCS curves also indicated that the higher the NLR, the higher the risk for PD, especially if the NLR value was <3.0. NLR during treatment could predict the risk of PD, suggesting that NLR could be integrated with tumor markers, computed tomographic images and other modalities to enable treatment selection without delay.

View Figures

View References

1	Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar
2	Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al: Nivolumab versus docetaxel in advanced nonsquamous Non-small-cell lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar
3	Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar
4	Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015. View Article : Google Scholar
5	Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 390:2461–2471. 2017. View Article : Google Scholar
6	Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, et al: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomized, open-label, phase 3 trial. Lancet. 398:27–40. 2021. View Article : Google Scholar
7	Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, et al: Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomized, multicentre, double-blind, Placebo-controlled, phase 3 trial. Lancet Oncol. 23:234–247. 2022. View Article : Google Scholar
8	Japanese Gastric Cancer Association, . Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 26:1–25. 2023. View Article : Google Scholar
9	Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al: Gastric cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 20:167–192. 2022. View Article : Google Scholar
10	Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A and Smyth EC; ESMO Guidelines Committee. Electronic address, : simpleclinicalguidelines@esmo.org: Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 33:1005–1020. 2022. View Article : Google Scholar
11	Iwasa S, Kudo T, Takahari D, Hara H, Kato K and Satoh T: Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy. Int J Clin Oncol. 25:1223–1232. 2020. View Article : Google Scholar
12	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
13	Hasegawa H, Fujitani K, Nakazuru S, Hirao M, Yamamoto K, Mita E and Tsujinaka T: Optimal treatment change criteria for advanced gastric cancer with Non-measurable peritoneal metastasis: Symptom/tumor Marker-based versus CT-based. Anticancer Res. 34:5169–5174. 2014.
14	Ota Y, Takahari D, Suzuki T, Osumi H, Nakayama I, Oki A, Wakatsuki T, Ichimura T, Ogura M, Shinozaki E, et al: Changes in the Neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Cancer Chemother Pharmacol. 85:265–272. 2020. View Article : Google Scholar
15	Namikawa T, Yokota K, Tanioka N, Fukudome I, Iwabu J, Munekage M, Uemura S, Maeda H, Kitagawa H, Kobayashi M, et al: Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer. Surg Today. 50:1486–1495. 2020. View Article : Google Scholar
16	Fujita K, Haruki N, Kurehara H, Ochi N, Yamakawa Y, Harata S, Tsumoto C, Tsuji T, Ito T, Izumi A, et al: Neutrophil-lymphocyte ratio as a prognostic indicator in patients treated with nivolumab for gastric cancer. Gan To Kagaku Ryoho. 47:923–926. 2020.(In Japanese).
17	Ogata T, Satake H, Ogata M, Hatachi Y, Inoue K, Hamada M and Yasui H: Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: A multicenter retrospective study. Oncotarget. 9:34520–34527. 2018. View Article : Google Scholar
18	Tsujimoto H, Ono S, Ichikura T, Matsumoto Y, Yamamoto J and Hase K: Roles of inflammatory cytokines in the progression of gastric cancer: Friends or foes? Gastric Cancer. 13:212–221. 2010. View Article : Google Scholar
19	Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar
20	Granja S, Tavares-Valente D, Queirós O and Baltazar F: Value of pH regulators in the diagnosis, prognosis and treatment of cancer. Semin Cancer Biol. 43:17–34. 2017. View Article : Google Scholar
21	Nakaya A, Kurata T, Yoshioka H, Takeyasu Y, Niki M, Kibata K, Satsutani N, Ogata M, Miyara T and Nomura S: Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int J Clin Oncol. 23:634–640. 2018. View Article : Google Scholar
22	Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 348:203–213. 2003. View Article : Google Scholar
23	Ohashi H, Takeuchi S, Miyagaki T and Kadono T: Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma. Drug Discov Ther. 14:117–121. 2020. View Article : Google Scholar
24	Nakao M, Muramatsu H, Kagawa Y, Suzuki Y, Sakai Y, Kurokawa R, Fujita K and Sato H: Immunological status may predict response to nivolumab in non-small cell lung cancer without driver mutations. Anticancer Res. 37:3781–3786. 2017.
25	Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y and Fujisawa M: C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. Int J Clin Oncol. 25:135–144. 2020. View Article : Google Scholar
26	Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H and Tomita M: Serum carcinoembryonic antigen level increases correlate with tumor progression in patients with differentiated gastric carcinoma following noncurative resection. Cancer Res. 50:3952–3955. 1990.
27	Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T and Kito T: The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol. 91:49–53. 1996.